- Accesswire•last month
Developing allosteric modulators to treat a wide range of CNS disorders; Report Available here: www.lifescicapital.com/equity-research/addex/ NEW YORK, NY / ACCESSWIRE / July 19, 2016 / LifeSci Capital, ...
- GlobeNewswire Europe•2 years agoAddex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia
Geneva, Switzerland /Chicago, USA, 19 January 2015 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development and the Dystonia Medical Research ...
We're sorry this is all we were able to find about this topic.
ADDEX N (ADXN.SW)
Swiss - Swiss Delayed Price. Currency in CHF
|Bid||2.85 x 50000|
|Ask||2.90 x 31800|
|Day's Range||2.82 - 2.90|
|52wk Range||2.15 - 3.56|
|1y Target Est||N/A|
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||24,230|
|Dividend & Yield||N/A (N/A)|